{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:20Z","timestamp":1793298920856,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euf.2026.05.009","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T19:53:08Z","timestamp":1779565988000},"page":"862-865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radioligand Therapy Hormone Combinations and the ENZA-p Trial"],"prefix":"10.1016","volume":"12","author":[{"given":"Louise","family":"Emmett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.05.009_b0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.05.009_b0010","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.05.009_b0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1084\/jem.20171052","article-title":"Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors","volume":"215","author":"Kaittanis","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.euf.2026.05.009_b0020","article-title":"PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression","volume":"4","author":"Caromile","year":"2017","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.euf.2026.05.009_b0025","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-21-4531","article-title":"Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer","volume":"28","author":"Sheehan","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2026.05.009_b0030","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1007\/s00259-025-07178-2","article-title":"Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study","volume":"52","author":"Unterrainer","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euf.2026.05.009_b0035","first-page":"92","article-title":"Modulation of PSMA expression by Androgen deprivation therapy (ADT): Serial PSMA PET in men with hormone sensitive, and castrate resistant prostate cancer commencing androgen blockade","volume":"59","author":"Emmett","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.009_b0040","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2967\/jnumed.120.259069","article-title":"Prospective, single-arm trial evaluating changes in uptake patterns on prostate-specific membrane antigen-targeted 18F-DCFPyL PET\/CT in patients with castration-resistant prostate cancer starting abiraterone or enzalutamide","volume":"62","author":"Zukotynski","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.009_b0050","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1470-2045(25)00339-0","article-title":"Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.05.009_b0055","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s43018-026-01140-3","article-title":"Predictive value of early PSMA upregulation for the response to enzalutamide \u00b1 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial","volume":"7","author":"Emmett","year":"2026","journal-title":"Nat Cancer"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:59:01Z","timestamp":1793296741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2405456926000775"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.05.009","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioligand Therapy Hormone Combinations and the ENZA-p Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}